TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
-0.55%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.51B
AUM Growth
+$111M
(+8%)
Cap. Flow
+$219M
Cap. Flow
% of AUM
14.5%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
194
New
40
Increased
63
Reduced
17
Closed
11
Top Buys
| 1 |
Galapagos
GLPG
|
$40.2M |
| 2 |
Relay Therapeutics
RLAY
|
$18.5M |
| 3 |
Replimune Group
REPL
|
$18.2M |
| 4 |
Legend Biotech
LEGN
|
$14.6M |
| 5 |
Immunocore
IMCR
|
$13.3M |
Top Sells
| 1 |
ITOS
iTeos Therapeutics
ITOS
|
$16.8M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$13M |
| 3 |
Immunome
IMNM
|
$10.5M |
| 4 |
ANI Pharmaceuticals
ANIP
|
$7.32M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$6.4M |
Sector Composition
| 1 | Healthcare | 94.65% |
| 2 | Technology | 1.65% |
| 3 | Communication Services | 1.35% |
| 4 | Consumer Discretionary | 0.56% |
| 5 | Financials | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
26
Avadel Pharmaceuticals
AVDL
$1.42B
| $15.7M | 1.04% |
1,497,500
+267,500
| +22% | +$2.81M |
|
27
Meta Platforms (Facebook)
META
$1.88T
| $15.6M | 1.03% |
26,600
+745
| +3% | +$436K |
|
|
28
Legend Biotech
LEGN
$6.41B
| $14.6M | 0.97% |
+450,000
| New | +$14.6M |
|
29
GSK
GSK
$79.5B
| $13.5M | 0.9% |
400,000
-50,000
| -11% | -$1.69M |
|
30
Sanofi
SNY
$112B
| $13M | 0.86% |
270,000
+200,000
| +286% | +$9.65M |
|
31
Liquidia Corp
LQDA
$2.45B
| $12.9M | 0.86% |
1,100,000
+300,000
| +38% | +$3.53M |
|
32
Viking Therapeutics
VKTX
$2.93B
| $12.9M | 0.85% |
320,000
+200,000
| +167% | +$8.05M |
|
33
Teladoc Health
TDOC
$1.36B
| $12.7M | 0.84% |
1,400,000
| – | – |
|
34
Moderna
MRNA
$9.31B
| $12.5M | 0.83% |
+300,000
| New | +$12.5M |
|
35
Kiniksa Pharmaceuticals
KNSA
$2.62B
| $12.4M | 0.82% |
628,609
| – | – |
|
|
CYBN
36
Cybin
CYBN
$145M
| $11.7M | 0.78% |
1,330,097
+930,097
| +233% | +$8.2M |
|
37
Vanda Pharmaceuticals
VNDA
$272M
| $11.3M | 0.75% |
2,353,307
| – | – |
|
38
Cullinan Oncology
CGEM
$405M
| $11.2M | 0.74% |
921,138
| – | – |
|
39
CRISPR Therapeutics
CRSP
$4.73B
| $10.5M | 0.69% |
266,500
| – | – |
|
40
Nuvation Bio
NUVB
$1.11B
| $10.4M | 0.69% |
3,900,000
| – | – |
|
41
HilleVax
HLVX
$105M
| $10.2M | 0.67% |
4,920,000
| – | – |
|
42
AstraZeneca
AZN
$254B
| $9.83M | 0.65% |
150,000
| – | – |
|
43
Elanco Animal Health
ELAN
$8.61B
| $9.69M | 0.64% |
800,000
+200,000
| +33% | +$2.42M |
|
44
Harmony Biosciences
HRMY
$2.11B
| $9.68M | 0.64% |
281,200
| – | – |
|
45
ADMA Biologics
ADMA
$4.01B
| $9.43M | 0.62% |
+550,000
| New | +$9.43M |
|
46
Rocket Pharmaceuticals
RCKT
$346M
| $9.43M | 0.62% |
750,000
| – | – |
|
|
CRGX
47
DELISTED
CARGO Therapeutics
CRGX
| $9.23M | 0.61% |
640,000
-60,749
| -9% | -$876K |
|
48
Design Therapeutics
DSGN
$338M
| $9.14M | 0.6% |
1,480,975
| – | – |
|
49
Compass Therapeutics
CMPX
$462M
| $8.56M | 0.57% |
5,900,000
+4,087,005
| +225% | +$5.93M |
|
50
Bausch + Lomb
BLCO
$5.16B
| $8.13M | 0.54% |
450,000
+100,000
| +29% | +$1.81M |
|